Scholarlink

<p>An increasing number of studies have indicated that cystatin C (CysC) may serve as an effective indicator for predicting the prognosis of renal cell carcinoma (RCC). However, there was currently a lack of meta-analysis examining the influence of serum CysC on the prognosis of RCC. From April 2016 to June 2024, we ultimately selected five retrospective studies including 1641 participants to evaluate the effect of serum CysC on patients with RCC. All data were analyzed using Review Manager version 5.3. The research findings primarily focused on overall survival (OS) and disease-free survival (DFS). Both univariate and multivariate analyses were conducted to evaluate the results. Five studies involving a total of 1641 patients were selected based on predefined eligibility criteria. Univariate analysis revealed that serum CysC levels were significantly correlated with OS (<i>P</i> &lt; 0.00001) and DFS (<i>P</i> = 0.02) in postoperative patients with RCC. Elevated serum CysC levels were considered a reliable predictor of poor prognosis in patients with RCC. Multivariate analysis indicated that high serum CysC levels were an independent risk factor for OS (<i>P</i> &lt; 0.00001) and DFS (<i>P</i> = 0.006) in postoperative patients with RCC, remaining unaffected by other factors. Our research results indicated that elevated serum CysC levels were associated with reduced OS and DFS in patients with RCC. However, caution must be exercised before making recommendations as this interpretation was based on very few clinical studies and small samples.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

The relationship between preoperative serum cystatin C levels and postoperative oncologic outcomes in patients with renal cell carcinoma: a systematic review and meta-analysis of 1641 patients

  • 期刊论文

  • 发表日期：

    2025年5月6日

查看全文
  • Shuai Lu,
  • Yulin Wang,
  • Zhongbao Zhou,
  • Yong Zhang,
  • Liqing Yang,
  • Xudong Yang

摘要

An increasing number of studies have indicated that cystatin C (CysC) may serve as an effective indicator for predicting the prognosis of renal cell carcinoma (RCC). However, there was currently a lack of meta-analysis examining the influence of serum CysC on the prognosis of RCC. From April 2016 to June 2024, we ultimately selected five retrospective studies including 1641 participants to evaluate the effect of serum CysC on patients with RCC. All data were analyzed using Review Manager version 5.3. The research findings primarily focused on overall survival (OS) and disease-free survival (DFS). Both univariate and multivariate analyses were conducted to evaluate the results. Five studies involving a total of 1641 patients were selected based on predefined eligibility criteria. Univariate analysis revealed that serum CysC levels were significantly correlated with OS (P < 0.00001) and DFS (P = 0.02) in postoperative patients with RCC. Elevated serum CysC levels were considered a reliable predictor of poor prognosis in patients with RCC. Multivariate analysis indicated that high serum CysC levels were an independent risk factor for OS (P < 0.00001) and DFS (P = 0.006) in postoperative patients with RCC, remaining unaffected by other factors. Our research results indicated that elevated serum CysC levels were associated with reduced OS and DFS in patients with RCC. However, caution must be exercised before making recommendations as this interpretation was based on very few clinical studies and small samples.